Showing 4361-4370 of 6037 results for "".
- Roflumilast Cream 0.3% Improves Patient-Reported Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/patient-reported-outcomes-improve-roflumilast-cream-03-psoriasis/2466998/A recent study suggested efficacy for roflumilast cream 0.3% for the topical treatment of plaque psoriasis. Researchers for the study pooled data from two Phase 3 clinical trials (DERMIS-1 and DERMIS-2), which included patients aged ≥2 years with plaque psoriasis affecting between 2% and
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Rinvoq Now Available for Pediatric Patients with Psoriatic Arthritis and Polyarticular Juvenile Idiopathic Arthritishttps://practicaldermatology.com/news/rinvoq-now-available-pediatric-patients-psoriatic-arthritis-and-polyarticular-juvenile-idiopathic-arthritis/2466955/AbbVie announced that its blockbuster drug Rinvoq (upadacitinib) is now indicated in the US for the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). The medication is indicated for those who had
- Survey Reveals Variation in Hyaluronidase Use in Aesthetic Practicehttps://practicaldermatology.com/news/survey-reveals-variation-hyaluronidase-use-aesthetic-practice/2466937/New research suggests a need for guidelines around the storage and dosing for hyaluronidase (HYAL) when using hyaluronic acid (HA) fillers. "Hyaluronic acids continue to be the fillers of choice worldwide and their popularity is growing," the authors wrote in Aesthetic Surgery Journa
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as
- Video-assisted Rhino-Septoplasty Technique Shows Validity: Studyhttps://practicaldermatology.com/news/video-assisted-rhino-septoplasty-technique-shows-validity-study/2466916/A new study suggests a video-guided rhino-septoplasty technique showed promise compared with more traditional techniques. "Conservative techniques have been developed in the field of rhinoplasty, focusing on limited tissue resection while emphasizing the reshaping of nasal structural elem
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Survey Shows Low Awareness, High Risk of Actinic Keratosis from Sun Exposurehttps://practicaldermatology.com/news/survey-shows-low-awareness-high-risk-actinic-keratosis-sun-exposure/2463197/A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. The survey, which included more than 2,500 participants aged 35 and older from Spain, Germany, Italy, the United Kingdom, and the United States, rev
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- A New, Proactive Approach to Newborn Skincarehttps://practicaldermatology.com/news/new-proactive-approach-newborn-skincare/2463138/Aveeno Baby announced the launch of Healthy Start, a proactive approach to newborn skincare featuring a wash and balm duo that are safe to use on newborn skin from birth. Aveeno Baby Healthy Start Newborn Wash is a nourishing cleanser made with prebiotic oat, oat extract, and glycerin to